What is Qvella?
Founded in 2009, Qvella operates at the intersection of biotechnology and clinical diagnostics. The company's core value proposition lies in its FAST technology, a novel sample treatment platform that enables rapid, accurate identification of pathogens. By streamlining the diagnostic workflow, Qvella addresses the urgent need for timely clinical interventions, which are essential for mitigating the impact of infectious diseases, reducing hospital length-of-stay, and lowering overall treatment costs. The company's market position is bolstered by its focus on high-impact, life-saving solutions that directly address the inefficiencies inherent in traditional laboratory testing protocols.
How much funding has Qvella raised?
Qvella has raised a total of $39.7M across 2 funding rounds:
Series A
$20M
Series B
$19.7M
Series A (2015): $20M, investors not publicly disclosed
Series B (2017): $19.7M led by Sands Capital, bioMérieux, Whitecap Venture Partners, RA Capital Advisors, and Hatteras Ventures
Key Investors in Qvella
Sands Capital
Established in 1992, Sands Capital Management is a prominent investment firm that manages equity mutual funds and maintains a strong presence in public equity markets.
bioMérieux
A French multinational leader in in vitro diagnostics, bioMérieux specializes in developing innovative solutions for the detection of infectious diseases and other critical health conditions.
Whitecap Venture Partners
Based in Toronto, this early-stage venture capital firm focuses on high-growth companies within the ICT, MedTech, and FoodTech sectors, providing deep operational expertise.
What's next for Qvella?
With the recent influx of capital, Qvella is well-positioned to advance its commercialization strategy and expand its footprint in the global diagnostics market. The company's roadmap likely includes scaling its manufacturing capabilities, pursuing regulatory milestones, and deepening its integration into hospital systems where rapid diagnostics are most critical. As the firm moves forward, the focus will remain on validating the clinical utility of its FAST platform across diverse healthcare settings. By leveraging the strategic support of its investor base, Qvella aims to solidify its role as a leader in the MedTech sector, ultimately driving a paradigm shift in how infectious diseases are managed and treated on a global scale.
See full Qvella company page
